Not yet recruiting
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
NCT07850063· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Recruiting
A study on the efficacy of a vaccine against influenza in adults ≥65 years of age
2026-526682-14-00· Phase 3· GlaxoSmithKline Biologicals· Source
Recruiting
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
NCT07474649· Phase 3· Daiichi Sankyo· Source
Contact: Fernando Cereto Castro
Recruiting
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
NCT07473128· Phase 3· Pharmacosmos A/S· Source
Recruiting
A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer
NCT07693751· Phase 1/2· SOTIO Biotech a.s.· Source
Not yet recruiting
An Open-label, Multicenter, Phase 1a/1b Study to Evaluate the Safety and Anti-tumor Activity of TT125-802 in Combination With Adagrasib, Osimertinib or Docetaxel in Patients with Advanced NSCLC
2024-519071-25-00· Phase 1· TOLREMO therapeutics AG· Source
Recruiting
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
NCT07305818· Phase 1· Merida Biosciences· Source
Active, not recruiting
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875· Phase 3· Kailera· Source
Recruiting
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
NCT07221188· Phase 3· GlaxoSmithKline· Source
Recruiting
Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient Women
NCT07308769· Phase 4· Pharmanutra S.p.a.· Source
Contact: Amparo Carrasco Mas, Dr.
Recruiting
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07244341· Phase 1· Daiichi Sankyo· Source
Recruiting
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.
2024-516906-47-00· Phase 2/3· Daiichi Sankyo Inc.· Source
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719· Phase 3· Arcus Biosciences, Inc.· Source
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236· Phase 1/2· BioNTech SE· Source
Active, not recruiting
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790· Phase 3· Arrowhead Pharmaceuticals· Source
Active, not recruiting
Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN)
2024-515538-34-00· Phase 2/3· Inhibrx Biosciences Inc.· Source
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514· Phase 3· Summit Therapeutics· Source
Active, not recruiting
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
NCT06687369· Phase 3· mAbxience Research S.L.· Source
Active, not recruiting
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC
2023-504753-12-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Recruiting
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
NCT06567015· Phase 1/2· Pierre Fabre Medicament· Source
Active, not recruiting
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866· Phase 3· Amgen· Source
Active, not recruiting
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721· Phase 3· Amgen· Source
Recruiting
First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer
2023-508435-31-00· Phase 1· Onkure Inc.· Source
Active, not recruiting
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441· Phase 2· Regeneron Pharmaceuticals· Source
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy
2023-508359-38-00· Phase 3· Amgen Inc.· Source
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· Phase 3· GlaxoSmithKline· Source
Recruiting
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations
2023-503865-48-00· Phase 2· Taiho Oncology Inc.· Source
Active, not recruiting
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
2023-503428-24-00· Phase 2· Glaxosmithkline Research & Development Limited· Source
Active, not recruiting
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337· Phase 3· DualityBio Inc.· Source
Active, not recruiting
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773· Phase 3· Taiho Oncology, Inc.· Source
Active, not recruiting
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738· Phase 3· Olema Pharmaceuticals, Inc.· Source
Active, not recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608· Phase 3· Summit Therapeutics· Source
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689· Phase 2· Taiho Oncology, Inc.· Source
Contact: Taiho Oncology, INC
Recruiting
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139· Phase 1/2· Eli Lilly and Company· Source
Recruiting
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
NCT05683418· Phase 1· Totus Medicines· Source
Recruiting
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717· Phase 1· Revolution Medicines, Inc.· Source
Active, not recruiting
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
NCT05425940· Phase 3· Exelixis· Source
Recruiting
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
NCT05413421· Phase 1· ORIC Pharmaceuticals· Source
Recruiting
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT05098132· Phase 1/2· Synthekine· Source
Active, not recruiting
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT05081609· Phase 1/2· Ascendis Pharma Oncology Division A/S· Source
Completed
ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study
NCT04431258· Phase 1/2· Ability Pharmaceuticals SL· Source
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722· Phase 1/2· enGene, Inc.· Source
Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
NCT03937154· Phase 3· Amgen· Source
Active, not recruiting
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166· Phase 1· Exelixis· Source
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977· Phase 1· Pfizer· Source
Active, not recruiting
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
NCT03260491· Phase 1· Daiichi Sankyo· Source